ScholarIQanswers from OpenAlex & ORCID
Aleix Prat
ResearcherPublications, citations & collaboration network
Aleix Prat is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Aleix Prat have?
ScholarIQindexed works
Aleix Prat has 1,346 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Aleix Prat have?
ScholarIQcitation count
Aleix Prat has 36,608 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Aleix Prat?
ScholarIQh-index
Aleix Prat has an h-index of 91 in OpenAlex.
What is the i10-index of Aleix Prat?
ScholarIQi10-index
Aleix Prat has an i10-index of 296 in OpenAlex.
What is the ORCID of Aleix Prat?
ScholarIQorcid
The ORCID for Aleix Prat is on the source record.
What is the OpenAlex record for Aleix Prat?
ScholarIQopenalex
The OpenAlex for Aleix Prat is on the source record.
What are the most-cited papers on Aleix Prat?
ScholarIQmost cited works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, Alejandra Flores-Chávez, Niamh M. Keegan, Munther A. Khamashta, Olivier Lambotte, Xavier Mariette, Aleix Prat, María E. Suarez‐Almazor
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Fátima Cardoso, Elżbieta Senkus, A. Costa, Efthymios Papadopoulos, Matti Aapro, Fabrice André, Nadia Harbeck, B. Aguilar Lopez, C.H. Barrios, Jonas Bergh, Laura Biganzoli, C.B. Boers-Doets, Maria João Cardoso, L.A. Carey, Javier Cortés, Giuseppe Curigliano, Véronique Dièras, Nagi S. El Saghir, Alexandru Eniu, Lesley Fallowfield, P.A. Francis, Karen A. Gelmon, S. Johnston, Bella Kaufman, Smruti Koppikar, I.E. Krop, Musa Mayer, Gertrude Nakigudde, B.V. Offersen, Shinji Ohno, Olivia Pagani, Shani Paluch–Shimon, Frédérique Penault‐Llorca, Aleix Prat, H.S. Rugo, G. W. Sledge, Danielle Spence, Christoph Thomssen, D.A. Vorobiof, B. Xu, Larry Norton, E.P. Winer
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Haley Ellis, Eneda Toska, Aleix Prat, Jessica J. Tao, Daniel E. Spratt, Nerissa T. Viola, Pau Castel, Gerard Minuesa, Natasha Morse, Jordi Rodón, Yasir H. Ibrahim, Javier Cortés, José Manuel Pérez-García, Patricia Galván, Judit Grueso, Marta Guzmán, John A. Katzenellenbogen, Michael G. Kharas, Jason S. Lewis, Maura N. Dickler, Violeta Serra, Neal Rosen, Sarat Chandarlapaty, Maurizio Scaltriti, José Baselga